
Aradigm Aradigm is a benefits platform for cell and gene therapies (CGT) designed to provide sustainable access to life-saving medicines. Aradigm’s novel financial and delivery model addresses the challenges facing every stakeholder — payers, providers, manufacturers, and, most importantly, patients. By creating a large-scale risk pool to cover and pay for all CGT drugs and care, with unspent funds returned, Aradigm can deliver cost predictability for employers and health plans. Aradigm’s end-to-end experience includes a national network of "centers of excellence” and concierge patient support, giving providers volume and rate certainty and patients appropriate, high-quality treatment and outcomes. A public benefit corporation, Aradigm is backed by Frist Cressey, Morgan Health, and Andreessen Horowitz. Service Provider

Aradigm

Aradigm is a benefits platform for cell and gene therapies (CGT) designed to provide sustainable access to life-saving medicines. Aradigm’s novel financial and delivery model addresses the challenges facing every stakeholder — payers, providers, manufacturers, and, most importantly, patients. By creating a large-scale risk pool to cover and pay for all CGT drugs and care, with unspent funds returned, Aradigm can deliver cost predictability for employers and health plans. Aradigm’s end-to-end experience includes a national network of "centers of excellence” and concierge patient support, giving providers volume and rate certainty and patients appropriate, high-quality treatment and outcomes. A public benefit corporation, Aradigm is backed by Frist Cressey, Morgan Health, and Andreessen Horowitz.

Service Provider